natgillin/translations-raw huggingface dataset:
Den hyppigste diagnose var blodforgiftning (candidaæmi) (77%, n=186)) og Candida- peritonitis (8%, n=19); patienter med Candida endocarditis, osteomyelitis eller meningitis blev holdt ude af denne undersøgelse.
The most frequent diagnoses were bloodstream infections (candidaemia) (77%, n=186) and Candida peritonitis (8%, n=19); patients with Candida endocarditis, osteomyelitis, or meningitis were excluded from this study.
Der administreredes, efter en bolusdosis på 70 mg, caspofungin 50 mg, én gang dagligt, mens amphotericin B administreredes med 0, 6- 0, 7 mg/ kg/ dag til patienter uden neutropeni og 0, 7- 1, 0 mg/ kg/ dag til patienter med neutropeni.
Caspofungin 50 mg once daily was administered following a 70-mg loading dose, while amphotericin B was administered at 0.6 to 0.7 mg/ kg/ day to non-neutropaenic patients or 0.7 to 1.0 mg/ kg/ day to neutropaenic patients.
224 patienter blev inkluderet i den primære effektanalyse (MITT analyse) af respons efter afslutning af IV - behandling; positive responsrater for behandling af invasiv candidiasis var sammenlignelige for caspofungin (73% [80/ 109]) og amphotericin B (62% [71/ 115]) [% forskel 12, 7 (95, 6% CI - 0, 7, 26, 0)].
Two hundred twenty-four patients were included in the primary efficacy analysis (MITT analysis) of response at the end of IV study therapy; favourable response rates for the treatment of invasive candidiasis were comparable for caspofungin (73% [80/ 109]) and amphotericin B (62% [71/ 115]) [% difference 12.7 (95.6% CI -0.7, 26.0)].
Blandt patienter med candidaæmi, var den positive respons rate efter endt IV- behandling sammenlignelig for caspofungin (72% (66/ 92)) og amphotericin B (63% (59/ 94)) i den primære effektanalyse (MITT analyse) [% forskel 10, 0 (95, 0% CI - 4, 5, 24, 5)]. Data fra patienter med ikke- blod infektionssteder var mere begrænsede.
Data in patients with non-blood sites of infection were more limited.
Gunstige responsrater hos patienter med neutropeni var 7/ 14 (50%) i caspofungin- gruppen og 4/ 10 (40%) i amphotericin B- gruppen.
Favourable response rates in neutropaenic patients were 7/ 14 (50%) in the caspofungin group and 4/ 10 (40%) in the amphotericin B group.
Af de patienter der fik
An independent expert panel determined that 41% (26/ 63) of patients receiving at least one dose of caspofungin had a favourable response.
22 mere end 7 dages behandling med caspofungin, havde 50% (26/ 52) gunstigt respons.
For those patients who received more than 7 days of therapy with caspofungin, 50% (26/ 52) had a favourable response.
36% (19/ 53) og 70% (7/ 10).
22 were 36% (19/ 53) and 70% (7/ 10), respectively.
Selvom doserne af tidligere anvendt antimykotisk behandling for 5 af patienterne, der var inkluderet som refraktære, var lavere end de doser der ofte gives for invasiv aspergillose, var raterne af gunstigt respons under caspofunginbehandling for disse patienter magen til dem set for resten af de refraktære patienter (henholdsvis 2/ 5 og 17/ 48).
Although the doses of prior antifungal therapies in 5 patients enrolled as refractory were lower than those often administered for invasive aspergillosis, the favourable response rate during therapy with caspofungin was similar in these patients to that seen in the remaining refractory patients (2/ 5 versus 17/ 48, respectively).
Af disse
Forty-nine patients were enrolled and received CANCIDAS at 50 mg/ m2 IV once daily following a 70-mg/ m2 loading dose on Day 1 (not to exceed 70 mg daily), of whom 48 were included in the MITT analysis.
23 patienter havde 37 invasiv candidiasis, 10 havde invasiv aspergillosis og 1 patient havde candidiasis i øsofagus.
Of these, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis.
Den gunstige responsfordeling, i henhold til indikation, var ved afslutningen af caspofunginbehandlingen følgende i MITT- analysen:
The favorable response rate, by indication, at the end of caspofungin therapy was as follows in the MITT
In vitro undersøgelser viser, at caspofungin ikke hæmmer cytokrom P450 enzymer 1A2, 2A6, 2C9, 2C19, 2D6 eller 3A4.
In vitro studies show that caspofungin is not an inhibitor of cytochrome P450 enzymes 1A2, 2A6, 2C9, 2C19, 2D6, or 3A4.
Der er ingen klinisk erfaring hos voksne patienter med svært nedsat leverfunktion
There is no clinical experience in adult patients with severe hepatic insufficiency and in paediatric patients with any degree of hepatic insufficiency.
4. 2).
24 hepatic impairment has been shown to provide an AUC similar to that obtained in adult subjects with normal hepatic function receiving the standard regimen (see section 4.2).
25 5. 3 Prækliniske sikkerhedsdata
25 5.3 Preclinical safety data
6. 3.
For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
26 6. 5 Emballage (art og indhold)
26 6.5 Nature and contents of container
10 ml Type I hætteglas med grå butylgummiprop og plastiklåg med gult/ orange aluminiumbånd til éngangsbrug.
10 ml Type I glass vials with a grey butyl stopper and a plastic cap with a yellow/ orange aluminium band for single use only.
Trin 1 Rekonstituering af almindelige hætteglas For at rekonstituere pulveret, bringes hætteglasset på stuetemperatur og der tilsættes langsomt og aseptisk 10, 5 ml vand til injektionsvæsker.
Step 1 Reconstitution of conventional vials To reconstitute the powder bring the vial to room temperature and aseptically add 10.5 ml of water for injections.
Koncentrationen af det rekonstituerede hætteglas vil være:
The concentrations of the reconstituted vials will be:
Det hvide/ brækket hvide, kompakte, lyofiliserede pulver vil opløses fuldstændig.
The white to off-white compact lyophilised powder will dissolve completely.
Natriumchlorid opløsning til injektionsvæsker eller Ringer - Lactat opløsning.
Step 2 Addition of Reconstituted CANCIDAS to patient infusion solution Diluents for the final solution for infusion are: sodium chloride solution for injection, or lactated Ringer’ s solution.
Infusioner med reduceret volumen af 100 ml kan anvendes for daglige doser på 50 eller 35 mg, hvis dette er nødvendigt af medicinske årsager.
Reduced volume infusions in 100 ml may be used, when medically necessary, for 50 mg or 35 mg daily doses.
27 TILBEREDNING AF OPLØSNING TIL INFUSION TIL VOKSNE
27 PREPARATION OF THE SOLUTION FOR INFUSION IN ADULTS
70 mg
70 mg 70 mg
70 mg (fra to 50 mg hætteglas) * 35 mg ved moderat
(from two 50 mg vials)** 35 mg for moderate
leverinsufficiens (fra et 70 mg hætteglas)
hepatic insufficiency (from one 70 mg vial)
0, 33 mg // ml
0.33 mg/ ml
* der skal anvendes 10, 5 ml ved rekonstituering af alle hætteglas ** hvis 70 mg hætteglas ikke er tilgængelige, kan 70 mg dosis tilberedes af to 50 mg hætteglas
* 10.5 ml should be used for reconstitution of all vials **If 70 mg vial is not available, the 70 mg dose can be prepared from two 50 mg vials
Tilberedning af 70 mg/ m2 infusion til børn > 3 måneder (ved brug af 70- mg hætteglas) 1.
Preparation of the 70 mg/ m2 infusion for paediatric patients > 3 months of age (using a 70-mg vial) 1.
Tilsæt aseptisk 10, 5 ml 0, 9% natriumchloridopløsning, sterilt vand til injektion eller bakteriostatisk vand til injektion med methylparaben og propylparaben. a Den rekonstituerede opløsning kan opbevares i op til en time ved ≤25°C (≤77°F). b Dette giver en endelig caspofunginkoncentration i hætteglasset på 7, 2 mg/ ml.
Aseptically add 10.5 ml of 0.9% Sodium Chloride Injection, Sterile Water for Injection or Bacteriostatic Water for Injection with methylparaben and propylparaben. a This reconstituted solution may be stored for up to one hour at ≤ 25°C (≤ 77°F). b This will give a final caspofungin concentration in the vial of 7.2 mg/ ml.
Tilberedning af 50 mg/ m2 infusion til børn > 3 måneder (ved brug af 70- mg hætteglas) 1.
Preparation of the 50 mg/ m2 infusion for paediatric patients > 3 months of age (using a 70-mg vial) 1.
Tilsæt aseptisk 10, 5 ml 0, 9% natriumchloridopløsning, sterilt vand til injektion eller bakteriostatisk vand til injektion med methylparaben og propylparaben. a Den rekonstituerede
Aseptically add 10.5 ml of 0.9% Sodium Chloride Injection, Sterile Water for Injection or Bacteriostatic Water for Injection with methylparaben and propylparaben. a This reconstituted
28 opløsning kan opbevares i op til en time ved ≤25°C (≤77°F). b Dette giver en endelig caspofunginkoncentration i hætteglasset på 7, 2 mg/ ml.
28 solution may be stored for up to one hour at ≤ 25°C (≤ 77°F). b This will give a final caspofungin concentration in the vial of 7.2 mg/ ml.
CANCIDAS er formuleret mhp at kunne give den fulde dosis, der er angivet på hætteglassets etiket (70 mg), når 10 ml trækkes op af hætteglasset.
CANCIDAS is formulated to provide the full labeled vial dose (70 mg) when 10 ml is withdrawn from the vial.
29 BILAG II
29 ANNEX II
INDEHAVER AF VIRKSOMHEDSGODKENDELSER ANSVARLIG FOR BATCHFRIGIVELSE
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Box 581, 2003 PC Haarlem, Holland
Box 581, 2003 PC Haarlem, The Netherlands
Virksomhedsgodkendelse udstedt den 21. marts 2001 af Ministerie van Volksgezondheid, Welzijn en Sport, Inspectie voor de gezondheidszorg van het Staatstoezicht op de Volksgezondheid, Postbus 16119, 2500 B. C.
Box 16119, 2500 B. C.
Haag, Holland.
The Hague, The Netherlands.
Produktresumé, afsnit 4. 2).
Summary of Product Characteristics, section 4.2)
• BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE SIKKER OG EFFEKTIV ANVENDELSE AF LÆGEMIDLET.
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Indehaveren af denne markedsføringstilladelse vil fortsat indsende periodiske sikkerhedsopdateringer hvert andet år.
The marketing Authorisation holder will continue to submit periodic safety update reports on a 2-year cycle.
31 BILAG III
31 ANNEX III
33 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
33 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
CANCIDAS 50 mg pulver til koncentrat til infusionsvæske, opløsning Caspofungin (som acetat)
CANCIDAS 50 mg powder for concentrate for solution for infusion Caspofungin (as acetate)
Hvert hætteglas indeholder:
Each vial contains:
50 mg caspofungin (som acetat).
50 mg caspofungin (as acetate).
Læs indlægsseddel før anvendelse.
Read the package leaflet before use.
35 MINDSTEKRAV TIL OPLYSNINGER, DER SKAL ANFØRES PÅ SMÅ INDRE EMBALLAGER
35 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
CANCIDAS 50 mg pulver til koncentrat til infusionsvæske, opløsning Caspofungin (som acetat) Intravenøs anvendelse.
CANCIDAS 50 mg powder for concentrate for solution for infusion Caspofungin (as acetate) Intravenous use
36 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
36 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
CANCIDAS 70 mg uplver til koncentrat til infusionsvæske, opløsning Caspofungin (som acetat)
CANCIDAS 70 mg powder for concentrate for solution for infusion Caspofungin (as acetate)
70 mg caspofungin (som acetat).
70 mg caspofungin (as acetate).
38 MINDSTEKRAV TIL OPLYSNINGER, DER SKAL ANFØRES PÅ SMÅ INDRE EMBALLAGER
38 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
CANCIDAS 70 mg pulver til koncentrat til infusionsvæske, opløsning Caspofungin (som acetat) Intravenøs anvendelse.
CANCIDAS 70 mg powder for concentrate for solution for infusion Caspofungin (as acetate) Intravenous use
40 INDLÆGSSEDDEL:
40 PACKAGE LEAFLET:
Læs denne indlægsseddel grundigt, inden De eller Deres barn begynder at bruge medicinen. • Gem indlægssedlen.
Read all of this leaflet carefully before you or your child start taking this medicine. • Keep this leaflet.
De kan få brug for at læse den igen. • Spørg lægen eller på apoteket, hvis der er mere, De vil vide. • Lægen har ordineret CANCIDAS til Dem eller deres barn personligt.
You may need to read it again. • If you have further questions, please ask your doctor or your pharmacist. • This medicine has been prescribed for you or your child.
Det kan være skadeligt for andre, selvom de har de samme symptomer, som De har. • Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller De får bivirkninger, som ikke er nævnt her.
It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Virkning og anvendelse 2.
What CANCIDAS is and what it is used for 2.
Det skal De vide, før De begynder at bruge CANCIDAS 3.
Before you take CANCIDAS 3.
Sådan skal De bruge CANCIDAS 4.
How to take CANCIDAS 4.
Opbevaring 6.
How to store CANCIDAS 6.
VIRKNING OG ANVENDELSE
WHAT CANCIDAS IS AND WHAT IT IS USED FOR
CANCIDAS er et svampedræbende lægemiddel, der påvirker produktionen af en bestanddel (glucanpolysaccharid) i svampens cellevæg, som er nødvendig for at svampen kan overleve og vokse.
CANCIDAS is an antifungal medicine that interferes with the production of a component (glucan polysaccharide) of the fungal cell wall that is necessary if the fungus is to continue living and growing.
Svampeceller, der udsættes for CANCIDAS, har ufuldstændige eller defekte cellevægge, som gør dem svage og ude af stand til at vokse.
Fungal cells exposed to CANCIDAS have incomplete or defective cell walls, making them fragile and unable to grow.
Lægen kan have ordineret CANCIDAS for at behandle en alvorlig svampeinfektion i kroppen.
CANCIDAS may have been prescribed to treat a serious fungal infection called invasive candidiasis.
Infektionen forårsages af svampeceller (gærceller) kaldet Candida.
The infection is caused by fungal (yeast) cells called Candida.
Disse gærceller findes naturligt i tarmsystemet og forårsager ikke infektion med mindre de kommer ind i blodet eller andre væv og organer, så som bughinde, hjerte, nyrer, lever, knogler, muskler, led, milt eller øjne.
These yeast cells are normally found in the digestive tract, and do not cause an infection unless they enter the bloodstream (in which case the infection is referred to as candidaemia) or other tissues or organs, such as the lining of the abdomen (peritonitis), the heart, the kidneys, the liver, bones, muscles, joints, spleen, or eyes.
Personer der har gennemgået operationer, og patienter med nedsat immunforsvar, har særlig høj risiko for alvorlig svampeinfektion.
Persons at high risk for invasive candidiasis include surgical patients and those whose immune systems are deficient.
Feber og kulderystelser der ikke afhjælpes af behandling mod bakterier er de hyppigste symptomer på denne type infektion.
Fever and chills that do not respond to antibacterial therapy are the most common symptoms of this type of infection.
Alternativt kan lægen også have ordineret CANCIDAS for at behandle en svampeinfektion i næse, bihuler eller lunger, fordi andre behandlinger mod svamp ikke har virket så godt som forventet, eller fordi de andre behandlinger mod svamp har givet bivirkninger.
Alternatively, your doctor may have prescribed CANCIDAS to treat a fungal infection in your nose, nasal sinuses, or lungs because other antifungal treatments have not been working as well as expected or because the other antifungal treatments are causing side effects.
Denne type infektion forårsages af organismer kaldet Aspergillus.
This infection is caused by organisms called Aspergillus.
Aspergillus- infektioner begynder i luftvejene (næse, bihuler eller lunger) fordi svampesporerne findes i den luft vi indånder hver dag.
Aspergillus fungal infections begin in the respiratory system (in the nose, sinuses, or lungs) because the spores of the fungus are found in the air we breathe every day.
Denne infektion kaldes invasiv aspergillose.
This infection is named invasive aspergillosis.
Svampen kan sprede sig til andre væv og organer.
It is possible for the fungus to spread to other tissues and organs.
Hos de fleste raske mennesker vil den naturlige evne til at bekæmpe sygdomme ødelægge disse svampesporer og fjerne dem fra kroppen.
In most healthy individuals, the natural ability to fight disease destroys the spores and removes them from the body.
Nogle sygdomstilstande mindsker kroppens modstandsdygtighed over for sygdom.
Some medical conditions lower the body’ s resistance to diseases.
Visse former for medicin, ordineret til patienter der har fået transplanteret et organ eller knoglemarv, kan også mindske kroppens modstandsdygtighed over for sygdom.
Also, certain medicines prescribed for patients who are organ or bone marrow recipients lower the body’ s resistance to diseases.
Det er disse patienter, der har størst risiko for at udvikle en Aspergillus- infektion.
These are the patients who are most likely to develop an Aspergillus infection.
Der kan opstå vedholdende febertilstand efter kemoterapi eller ved medicinske forhold, som mindsker kroppens modstandskraft overfor sygdom ved at nedsætte antallet af visse hvide blodceller.
Persistent fever due to infection may occur following chemotherapy or medical conditions that lower the body’ s resistance to disease by lowering counts of certain white blood cells.
Hvis feberen ikke falder ved behandling med antibiotika kan Deres læge mistænke, at De har en svampeinfektion og derfor ordinere CANCIDAS til at behandle denne tilstand.
If the fever is not reduced by treatment with an antibiotic, your doctor may suspect that you have a fungal infection and prescribe CANCIDAS to treat it.
41 2.
41 2.
DET SKAL DE VIDE, FØR DE BEGYNDER AT BRUGE CANCIDAS
BEFORE YOU TAKE CANCIDAS
De må ikke bruge CANCIDAS
Do not take CANCIDAS
- Hvis De er overfølsom (allergisk) over for det aktive stof eller et af de øvrige indholdsstoffer i
- if you are hypersensitive (allergic) to caspofungin or any of the other ingredients of
Vær ekstra forsigtig med at bruge CANCIDAS
Take special care with CANCIDAS
- Hvis De har, eller har haft, leverproblemer.
- if you have had or now have liver problems.
Nogle patienter med leversygdom, kan have
Some patients with liver problems may require a
behov for ændret dosis
dosage adjustment.
- Hvis De anvender ciclosporin (et lægemiddel, der hjælper mod, at transplanterede organer
- if you are taking cyclosporin, a medicine to help prevent organ transplant rejection or to treat
frastødes eller til behandling af visse problemer med immunsystemet).
certain problems with your immune system.
Lægen kan tage yderligere blodprøver under behandlingen
Your physician may order additional blood tests during your treatment.
- Hvis De lider af allergier
- if you have any allergies.
Fortæl lægen om eventuelle helbredsproblemer De har eller har haft.
Tell your doctor about any medical conditions you have or have had.
CANCIDAS er godkendt til brug hos børn og unge til alle de infektionstyper, der er beskrevet ovenfor.
CANCIDAS has been approved for use in children and adolescents for all the infection types described above.
Dosis til børn kan være forskellig fra den dosis, der skal bruges til voksne patienter.
The dose used in paediatric patients may differ from the dose used in adult patients.
Lægen beslutter om dosis af anden medicin eventuelt skal tilpasses.
Your physician will determine if any adjustments should be made to other medicines you may be taking.
Hvis De behandles med ciclosporin, vil Deres læge muligvis tage yderligere blodprøver under behandlingen.
If you are receiving cyclosporine, your physician may order additional blood tests during your treatment.
Derudover skal De fortælle lægen om al anden medicin, De anvender eller planlægger at anvende, også medicin der kan købes uden recept.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Det er særlig vigtigt, at De fortæller lægen, om De anvender bestemte lægemidler mod HIV- infektion (inklusiv efavirenz og nevirapin), epilepsimidlerne fenytoin og carbamazepin, binyrebarkhormonet dexamethason, det antibiotiske lægemiddel rifampicin og det immunhæmmende lægemiddel tacrolismus.
It is particularly important for your doctor to know if you are taking certain anti-HIV medicines (including efavirenz or nevirapine), the antiseizure (epilepsy) medicines phenytoin and carbamazepine, the steroid dexamethasone, the antibiotic rifampicin, and the immunosuppressant tacrolimus.
Gravide kvinder må kun behandles med CANCIDAS hvis det skønnes, at fordelene opvejer den mulige risiko for fostret.
CANCIDAS has not been studied in pregnant women, and should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.
Kvinder, der behandles med CANCIDAS, bør ikke amme.
Women receiving CANCIDAS should not breast-feed.
Spørg lægen til råds, inden De anvender nogen form for medicin.
Ask you doctor for advice before taking any medicine.
Der findes ingen oplysninger om, at CANCIDAS påvirker evnen til at køre bil eller betjene maskiner.
There is no information to suggest that CANCIDAS affects your ability to drive or operate machinery.
Vigtig information om nogle af de øvrige indholdsstoffer i CANCIDAS CANCIDAS indeholder saccharose.
CANCIDAS contains sucrose.
Hvis De af Deres læge har fået af vide, at De er overfølsom over for visse sukkerarter, skal De kontakte Deres læge, før De anvender denne medicin.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
SÅDAN SKAL DE BRUGE CANCIDAS
HOW TO TAKE CANCIDAS
CANCIDAS vil altid blive blandet og givet til Dem af en læge eller sygeplejerske.
CANCIDAS will always be prepared and given to you by a doctor or another healthcare professional.
1 time.
42 CANCIDAS should be administered once daily by slow intravenous infusion over approximately 1 hour.
Lægen bestemmer behandlingens varighed og hvor meget CANCIDAS, De skal have hver dag.
Your physician will determine the duration of your treatment and how much CANCIDAS you will receive each day.
Lægen vil overvåge hvordan De reagerer på medicinen og hvordan De har det.
He will monitor your response and condition.
Det er ikke nødvendigt at ændre dosis afhængigt af alder eller hvis De lider af nedsat nyrefunktion.
The dose will not need to be adjusted according to your age or if you are suffering from renal impairment.
Hvis De har moderat eller svært nedsat leverfunktion eller vejer mere end 80 kg kan en ændring af dosis være nødvendig.
If you weigh more than 80 kg, a dose adjustment may be required.
Hvis De har brugt for meget CANCIDAS
If you take more CANCIDAS than you should
Lægen vil overvåge hvordan De reagerer på medicinen og hvordan De har det for at fastlægge, hvilken behandling med CANCIDAS der er nødvendig.
Your doctor will monitor your response and condition to determine what CANCIDAS treatment is needed.
Hvis De er bekymret for, om De måske har fået for meget CANCIDAS, skal De kontakte lægen eller andet sundhedspersonale med det samme.
However, if you are concerned that you may have been given too much CANCIDAS, contact your doctor or another healthcare professional immediately.
Hvis De har glemt at bruge CANCIDAS
If you miss/ forget to take a dose of CANCIDAS
Deres læge vil overvåge hvordan De reagerer på medicinen og hvordan De har det for at fastlægge, hvilken behandling med CANCIDAS der er nødvendig.
Your doctor will monitor your response and condition to determine what CANCIDAS treatment is needed.
Hvis De er bekymret for, om De måske har sprunget en dosis CANCIDAS over, skal De kontakte lægen eller andet sundhedspersonale med det samme.
However, if you are concerned that you may have missed a dose, contact your doctor or another healthcare professional immediately.
Hvis De holder op med at bruge CANCIDAS
If you stop taking CANCIDAS
Der er ingen kendte symptomer ved afslutning af behandling.
There are no known withdrawal symptoms.
CANCIDAS kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, CANCIDAS can cause side effects, although not everybody gets them.
De følgende termer beskriver hvor ofte bivirkninger har været rapporteret.
The following terms are used to describe how often side effects have been reported.